The estimated Net Worth of Luisa M Stamm is at least $2.85 Million dollars as of 29 March 2022. Luisa Stamm owns over 1,038 units of Assembly Biosciences Inc stock worth over $700,675 and over the last 5 years he sold ASMB stock worth over $24,677. In addition, he makes $2,126,470 as Chief Medical Officer at Assembly Biosciences Inc.
Sign up
Luisa Stamm ASMB stock SEC Form 4 insiders trading
Luisa has made over 2 trades of the Assembly Biosciences Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 1,038 units of ASMB stock worth $2,252 on 29 March 2022.
The largest trade he's ever made was selling 4,397 units of Assembly Biosciences Inc stock on 9 November 2020 worth over $22,425. On average, Luisa trades about 1,359 units every 126 days since 2019. As of 29 March 2022 he still owns at least 40,315 units of Assembly Biosciences Inc stock.
You can see the complete history of Luisa Stamm stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Luisa Stamm biography
Dr. Luisa M. Stamm serves as Chief Medical Officer of the Company. Prior to joining, Dr. Stamm served in a series of positions of increasing responsibility in the clinical research group at Gilead from July 2013 through November 2019, culminating in her role as Executive Director, Clinical Research. Prior to joining Gilead, Dr. Stamm was an instructor at Harvard Medical School from January 2013 until July 2013. From 2009 until July 2013, Dr. Stamm was a clinical and research fellow in infectious disease at Massachusetts General Hospital. Dr. Stamm received a B.A. in Biochemistry from Harvard University and an M.D. and a Ph.D. in Biomedical Sciences from the University of California, San Francisco.
What is the salary of Luisa Stamm?
As the Chief Medical Officer of Assembly Biosciences Inc, the total compensation of Luisa Stamm at Assembly Biosciences Inc is $2,126,470. There are 3 executives at Assembly Biosciences Inc getting paid more, with John McHutchison having the highest compensation of $7,007,210.
How old is Luisa Stamm?
Luisa Stamm is 44, he's been the Chief Medical Officer of Assembly Biosciences Inc since 2019. There are 18 older and no younger executives at Assembly Biosciences Inc. The oldest executive at Assembly Biosciences Inc is Alan Lewis, 74, who is the Independent Director.
What's Luisa Stamm's mailing address?
Luisa's mailing address filed with the SEC is C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD., FOURTH FLOOR, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Assembly Biosciences Inc
Over the last 10 years, insiders at Assembly Biosciences Inc have traded over $1,523,622 worth of Assembly Biosciences Inc stock and bought 1,245,980 units worth $1,060,065 . The most active insiders traders include Sciences, Inc. Gilead, Myron Z Holubiak und Helen Susan Kim. On average, Assembly Biosciences Inc executives and independent directors trade stock every 46 days with the average trade being worth of $389,399. The most recent stock trade was executed by Nicole S White on 2 August 2024, trading 785 units of ASMB stock currently worth $11,171.
What does Assembly Biosciences Inc do?
assembly biosciences, inc. (nasdaq: asmb) is a public clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and novel oral live biotherapeutics for disorders associated with the microbiome. assembly is developing two innovative platform programs: an hbv program advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and a microbiome program developing novel oral live biotherapeutics designed to address diseases associated with the microbiome. assembly’s hbv program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic hbv. the company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current good manufacturing practices and a patent-pending delivery system, gemicel®, which allows for targeted ora
What does Assembly Biosciences Inc's logo look like?
Complete history of Luisa Stamm stock trades at Assembly Biosciences Inc
Assembly Biosciences Inc executives and stock owners
Assembly Biosciences Inc executives and other stock owners filed with the SEC include:
-
John McHutchison,
President, Chief Executive Officer, Director -
Jacqueline Papkoff,
Senior Vice President, Chief Scientific Officer Microbiome -
Thomas Joseph Russo,
Chief Financial Officer -
Luisa Stamm,
Chief Medical Officer -
Dr. John G. McHutchison A.O., FRACP, M.D.,
CEO, Pres & Director -
Jason A. Okazaki,
Chief Operating Officer -
Dr. William E. Delaney IV, Ph.D.,
Chief Scientific Officer -
William Ringo,
Non-Executive Independent Chairman of the Board -
Myron Holubiak,
Independent Director -
Alan Lewis,
Independent Director -
Anthony Altig,
Independent Director -
Susan Mahony,
Independent Director -
Richard DiMarchi,
Independent Director -
Helen Kim,
Independent Director -
Nicole White,
Senior Vice President - Pharmaceutical Development and Manufacturing -
Gina Consylman,
Independent Director -
Jason Okazaki,
Chief Legal and Business Officer -
William Delaney,
Chief Scientific Officer - Virology -
Steven Knox,
Senior Vice President - Clinical Development -
David Houck,
Senior Vice President - Product Development and Portfolio Management -
Michele Anderson,
Chief Devel. Officer -
Dr. Tharaknath Rao,
Head of Microbiome Clinical Devel. & Sr. VP -
Dr. Richard J. Colonno,
Sr. Advisor -
Jennifer A. Troia MHROD, SHRM-SCP, SPHR,
Chief HR Officer -
Lauren Glaser,
Sr. VP of Investor Relations & Corp. Affairs -
Michael P. Samar,
CFO & Principal Accounting Officer -
Dr. Adam Zlotnick,
Co-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory Board -
Dr. Uri A. Lopatin M.D.,
Co-Founder and Clinical & Scientific Advisor -
Graham K Cooper,
See Remarks -
Mark Auerbach,
Director -
David Jonathan Barrett,
See Remarks -
Thomas E Rollins,
Chief Development Officer -
Uri A Lopatin,
Chief Medical Officer -
Michael Houghton,
-
Derek A Small,
Director -
Richard James Colonno,
EVP & CSO, Virology Ops -
Capital Fund Qualified, L.P...,
10% owner -
Lisa Johnson Pratt,
-
Anuj Gaggar,
Chief Medical Officer -
Adam Zlotnick,
10% owner -
Sciences, Inc. Gilead,
10% owner -
Michael P. Samar,
Chief Financial Officer -
Jeanette M Bjorkquist,
Principal Accounting Officer -
Alexander Schornstein,
10% owner